Abu Dhabi Develops AI Tool to Speed Up MS Diagnosis
<p><strong>Abu Dhabi, September 18, 2025</strong> – Abu Dhabi has taken a major step in advancing neurological care with the creation of an <strong>AI-powered MRI diagnostic tool</strong> designed to improve the detection of <strong>multiple sclerosis (MS)</strong>. The breakthrough stems from a collaboration between <strong>New York University Abu Dhabi (NYUAD)</strong>, <strong>Yas Clinic – Khalifa City</strong>, and the <strong>Abu Dhabi Stem Cells Center (ADSCC)</strong>, reflecting the UAE’s ambition to establish itself as a global hub for healthcare innovation.</p><h3>Tackling a diagnostic challenge</h3><p>Multiple sclerosis, a chronic condition that affects the central nervous system, is notoriously difficult to diagnose. Traditional MRI scans often reveal brain lesions that resemble those caused by other disorders such as migraines, vascular diseases, or autoimmune conditions. This similarity frequently leads to diagnostic uncertainty, requiring months of monitoring, repeat imaging, and sometimes invasive tests before a clear diagnosis is made.</p><p>Early treatment is critical in managing MS effectively, but these delays can prevent patients from accessing care at the most crucial stages of the disease.</p><h3>FLAIRstar: AI innovation in MRI scans</h3><p>At the core of this initiative is <strong>FLAIRstar</strong>, an advanced computational module developed by researchers at <strong>NYUAD’s Center for Brain and Health (CBH)</strong>. The tool automatically detects the <strong>central vein sign (CVS)</strong>, a tiny vein visible at the center of brain lesions. This marker was officially recognized under the <strong>McDonald 2024 criteria</strong> as one of the most reliable biomarkers for confirming MS.</p><p>By identifying CVS with high precision, FLAIRstar enables neurologists to distinguish MS lesions from those of other conditions, dramatically reducing the uncertainty that has long challenged doctors and patients alike.</p><h3>Clinical validation in Abu Dhabi</h3><p>Over the past two years, the partnership has worked to bring NYUAD’s imaging innovations into real-world clinical use. At <strong>Yas Clinic – Khalifa City</strong>, FLAIRstar is being applied within the <strong>LAMINATE project</strong>, which integrates cutting-edge MRI techniques into patient care while ensuring all medical data is securely managed within the UAE.</p><p>Dr. <strong>Lev Brylev</strong>, Consultant Neurologist at Yas Clinic, emphasized the clinical impact of the project:</p><blockquote><p><i>“Through our collaboration with NYUAD, we are combining medical expertise with advanced MRI methods to deliver transformative solutions for MS care. Tools like FLAIRstar and LAMINATE are already improving diagnostic accuracy, reducing delays, and ultimately enhancing patient outcomes.”</i></p></blockquote><h3>Expanding research into new therapies</h3><p>The collaboration is not limited to diagnostics. NYUAD’s imaging expertise is also being used in Yas Clinic’s <strong>PHOMS clinical trial</strong>, which tracks subtle brain changes in MS patients. The trial is evaluating the effectiveness of <strong>Extracorporeal Photopheresis (ECP)</strong>, an emerging therapy aimed at slowing disease progression.</p><p>This integration of <strong>AI diagnostics</strong> and <strong>therapeutic monitoring</strong> underscores Abu Dhabi’s strategy of building a healthcare ecosystem where research and clinical practice work hand in hand.</p><h3>A “bench-to-bedside” success story</h3><p>Professor <strong>Osama Abdullah</strong>, MRI Physicist at NYUAD’s Center for Brain and Health, highlighted the importance of translating academic research into direct patient benefit:</p><blockquote><p><i>“This is a perfect example of the ‘bench-to-bedside’ journey. Our research expands the possibilities of what MRI can reveal, but it is through partnerships with Yas Clinic and ADSCC that these discoveries come to life in patient care. Together, we are building an ecosystem of innovation in Abu Dhabi.”</i></p></blockquote><h3>UAE’s role in global medical innovation</h3><p>The initiative comes as the UAE accelerates its investment in <strong>AI-driven healthcare solutions</strong>. By merging academic excellence with clinical expertise, Abu Dhabi is positioning itself as a regional and global leader in tackling complex neurological conditions.</p><p>For patients living with MS in the UAE and beyond, the combination of faster diagnosis and improved monitoring offers renewed hope for more effective treatment and better long-term outcomes.</p><p><strong>In summary</strong>, the creation of FLAIRstar and its deployment through Abu Dhabi’s healthcare system illustrate how strategic partnerships can transform research breakthroughs into tangible medical progress. As the UAE continues to advance in life sciences and medical technology, projects like this highlight its growing role in shaping the future of global healthcare.</p>